[Dose intensity in M-VAC chemotherapy with XXXX for metastatic transitional urothelial cancer].

@entity632 @entity1 @entity5 @entity900 @entity7420 @entity3 @entity1499 @entity5713
The effect of M-VAC ( @entity1499 , @entity5713 , @entity632 and @entity900 ) chemotherapy supported recombinant @entity1 granulocyte stimulating factor ( @entity7420 ) was studied in 18 @entity1 with metastatic @entity5 . The mean age of the @entity1 was 66 years. Of the @entity1 6 had lung @entity3 and 12 had distant lymph node @entity3 . In this study recombinant @entity1 granulocyte stimulating factor was administered therapeutically at 100 to 250 micrograms subcutaneously after the white blood cell count was less than 3,000/mm. Relative dose-intensity (RDI) was 0.88 +/- 0.11 and 0.72 +/- 0.19 for 11 @entity1 with @entity7420 and 7 without @entity7420 , respectively. The relative dose regardless of the interval of the cycle of M-VAC chemotherapy (%Dose) was 0.95 +/- 0.06 and 0.86 +/- 0.09 for the @entity1 with @entity7420 and those without @entity7420 , respectively. Of seven @entity1 without @entity7420 3 @entity1 responded (response rate 42%, mean survival period 7.4 months). Of 11 @entity1 treated with @entity7420 3 @entity1 responded (response rate 72.7%, mean survival period 20.0 months). Although @entity7420 increased the RDI of M-VAC chemotherapy, the correlation of response with RDI was not clearly demonstrated. The therapeutical administrations of @entity7420 fail to improve the mean white blood cell nadir and to prevent the decrease of the platelet and reticulocyte count.
